{"product_id":"pgp9-5-antibody-uchl1-bha17109983","title":"PGP9.5 Antibody \/ UchL1","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003ePGP9.5 Antibody \/ UchL1 is a research-use antibody directed against \u003cstrong\u003ePGP9.5\u003c\/strong\u003e. It is supplied for use in common immunoassay contexts such as WB, IHC-P (RUO).\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e PGP9.5.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eDescription (provided):\u003c\/strong\u003e The protein encoded by the UCHL1 gene belongs to the peptidase C12 family.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eAntibody type:\u003c\/strong\u003e Rabbit, clone AOCE-21, Rabbit IgG.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified; Affinity purified.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e tested: Human.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eImmunogen (if provided):\u003c\/strong\u003e A synthetic peptide specific to human PGP9.5 \/ UCHL1 was used as the immunogen for the PGP9.5 antibody..\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe information above helps you match the antibody format to your assay context, interpret species-dependent differences, and anticipate how epitope context (isoforms, PTMs, or conformational state) may influence signal.\u003c\/p\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003eThe protein encoded by the UCHL1 gene belongs to the peptidase C12 family. This enzyme is a thiol protease that hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. This gene is specifically expressed in the neurons and in cells of the diffuse neuroendocrine system. Mutations in this gene may be associated with Parkinson disease.\u003c\/p\u003e\n\u003cp\u003eFor curated annotations (gene\/protein naming, domains, isoforms, and pathway links) for PGP9.5, consult primary databases such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e\n\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eContext-dependent expression studies: researchers often examine PGP9.5 abundance and localization across perturbations (genetic, pharmacologic, or environmental) to connect phenotype to molecular changes.\u003c\/li\u003e  \u003cli\u003eReagent reproducibility: there is growing emphasis on antibody specificity checks using orthogonal approaches (e.g., genetic perturbation or independent antibodies) and transparent reporting of clone\/lot information.\u003c\/li\u003e  \u003cli\u003eMulti-modal datasets: antibody-based readouts are increasingly combined with transcriptomics and imaging to relate protein-level measurements to cell-state transitions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eWestern blotting (immunoblot) for relative detection of target protein abundance and apparent molecular weight.\u003c\/li\u003e  \u003cli\u003eImmunohistochemistry for spatial mapping of target expression across tissues and cell types.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhen comparing conditions, interpret changes in signal in the context of sample composition, expected localization, and any known isoform complexity for the target.\u003c\/p\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e alternative splicing or post-translational modifications can change epitope accessibility and apparent molecular weight; interpret bands\/signals accordingly.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eCross-reactivity and matrix effects:\u003c\/strong\u003e background binding can vary by sample type, species, and blocking\/detection chemistries; include appropriate negative controls.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e where feasible, use genetic perturbation (KO\/KD\/overexpression), orthogonal assays, or independent antibodies to support specificity claims.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAntibody considerations:\u003c\/strong\u003e Polyclonal reagents may recognize multiple epitopes and can increase sensitivity but may show broader binding profiles, while monoclonal clones provide a single-epitope readout that can improve consistency across experiments. If a conjugate is listed, the antibody supports more direct detection workflows; otherwise, it is typically used with a compatible secondary antibody.\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProtKB entry for PGP9.5 (UniProt): https:\/\/www.uniprot.org\/uniprotkb\/P09936\n- NCBI Gene search for PGP9.5 (NCBI): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=PGP9.5\n- Ensembl gene search for PGP9.5 (Ensembl): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=PGP9.5\n- Antibody validation “5 pillars” (Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995\n- NIH replication \u0026 reproducibility resources (NIH): https:\/\/www.nih.gov\/replicationandreproducibility\n- Human Protein Atlas search for PGP9.5 (HPA): https:\/\/www.proteinatlas.org\/search\/PGP9.5\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"Antibody in PBS with 0.02% sodium azide, 50% glycerol and 0.4-0.5mg\/ml BSA \/ 100 ul","offer_id":53044505018733,"sku":"RQ5295","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_196a9efc-e243-4960-9958-802e0d63d422.jpg?v=1771939053","url":"https:\/\/www.ebiohippo.com\/products\/pgp9-5-antibody-uchl1-bha17109983","provider":"BioHippo","version":"1.0","type":"link"}